Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

Vizimpro (dacomitinib) for the Treatment of Non-Small Cell Lung Cancer

Paronychia is one of the most common adverse events noticed in patients during the clinical trial on Vizimpro®.

  • Vizimpro®
  • Vizimpro®
  • Vizimpro

Go Top